ADMA Biologics, Inc. (ADMA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Syndax Pharmaceuticals, Inc.

ADMA Biologics, Inc.

Prime Medicine, Inc.

Relay Therapeutics, Inc.

Protagonist Therapeutics, Inc.

Dianthus Therapeutics, Inc.

Immatics NV

Rayzebio, Inc.

Cogent Biosciences, Inc.

Replimune Group, Inc.

Pliant Therapeutics, Inc.

Why is ADMA Biologics, Inc. ?

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 66.33%

The company has declared Positive results for the last 17 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 76.71 MM
INTEREST COVERAGE RATIO(Q) Highest at 2,445.86
RAW MATERIAL COST(Y) Fallen by -3.09% (YoY)

With ROE of 55.71%, it has a attractive valuation with a 13.18 Price to Book Value

Over the past year, while the stock has generated a return of 1.07%, its profits have risen by 823.3% ; the PEG ratio of the company is 0

Underperformed the market in the last 1 year

The stock has generated a return of 1.07% in the last 1 year, much lower than market (S&P 500) returns of 11.96%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to ADMA Biologics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is ADMA Biologics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

ADMA Biologics, Inc.

6.27%

1.53

51.97%

S&P 500

11.09%

0.60

19.84%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

66.33%

EBIT Growth (5y)

38.33%

EBIT to Interest (avg)

0.77

Debt to EBITDA (avg)

0.83

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

0.93

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

98.05%

ROCE (avg)

11.78%

ROE (avg)

14.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

13.18

EV to EBIT

32.38

EV to EBITDA

30.78

EV to Capital Employed

13.11

EV to Sales

10.72

PEG Ratio

0.03

Dividend Yield

ROCE (Latest)

40.49%

ROE (Latest)

55.71%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 76.71 MM

INTEREST COVERAGE RATIO(Q)

Highest at 2,445.86

RAW MATERIAL COST(Y)

Fallen by -3.09% (YoY

NET PROFIT(9M)

Higher at USD 175.25 MM

NET SALES(Q)

Highest at USD 121.98 MM

OPERATING PROFIT(Q)

Highest at USD 44.86 MM

PRE-TAX PROFIT(Q)

Highest at USD 41.26 MM

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.78 times

Here's what is working for ADMA Biologics, Inc.

Net Profit

At USD 175.25 MM has Grown at 200.1%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (USD MM)

Interest Coverage Ratio

Highest at 2,445.86 and Grown

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow

Highest at USD 76.71 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 121.98 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 44.86 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD 41.26 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Higher at USD 175.25 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (USD MM)

Raw Material Cost

Fallen by -3.09% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 2.06 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for ADMA Biologics, Inc.

Debtors Turnover Ratio

Lowest at 6.78 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio